James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), filed a Form 4 on November 12, 2026, reporting stock option exercises and open-market sales of common stock on November 9 and November 10, 2026, executed under a Rule 10b5-1 trading plan.
Key Highlights
- Trading plan in effect: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on April 10, 2026.
- Options exercised: Frates exercised 20,000 stock options on each of November 9 and November 10, 2026, at an exercise price of $6.88 per share, for a combined total of 40,000 shares acquired.
- Shares sold on November 9: 7,700 shares at a weighted average price of $29.3887 and 12,300 shares at a weighted average price of $30.1105 were disposed of.
- Shares sold on November 10: 12,800 shares at a weighted average price of $30.3209 and 7,200 shares at a weighted average price of $30.9698 were disposed of.
- Direct ownership after transactions: Following all reported transactions, Frates directly held 233,625 shares of common stock.
- Indirect holdings: An additional 166,531 shares are held indirectly across four trusts for which Frates serves as trustee, with beneficial ownership disclaimed for Section 16 purposes except to the extent of his pecuniary interest.
- Remaining options: Following the two exercises, Frates held 323,835 stock options (right to buy) with an exercise price of $6.88 and an expiration date of January 25, 2031, all of which are fully vested and exercisable.
Frates Option Exercises and Sales Under 10b5-1 Plan at Amylyx Pharmaceuticals
According to the filing, James M. Frates, serving as Chief Financial Officer of Amylyx Pharmaceuticals, Inc., reported six transactions in Amylyx common stock across two trading days. On November 9 and November 10, 2026, he exercised stock options under transaction code "M," acquiring 20,000 shares each day at the stated exercise price of $6.88 per share. The underlying options carry an expiration date of January 25, 2031, and the filing states they are "fully vested and exercisable."
On each day, Frates also disposed of shares under transaction code "S." On November 9, he sold 7,700 shares at a weighted average of $29.3887 (with individual sale prices ranging from $28.81 to $29.71) and 12,300 shares at a weighted average of $30.1105 (ranging from $29.82 to $30.29). On November 10, he sold 12,800 shares at a weighted average of $30.3209 (ranging from $29.86 to $30.73) and 7,200 shares at a weighted average of $30.9698 (ranging from $30.905 to $31.15). All weighted average prices in the filing are noted as such, with full per-transaction detail available to SEC staff upon request.
In addition to 233,625 directly held shares following the reported transactions, the filing identifies four trusts holding Amylyx common stock indirectly: the James M. Frates 2025 GRAT No. 1 (100,000 shares), the James M. Frates 2024 Grantor Retained Annuity Trust No. 1 (15,459 shares), the Frates Family 2013 Irrev Trust (11,072 shares), and the James M. Frates 2026 Grantor Retained Annuity Trust No. 1 (40,000 shares). The filing states that Frates disclaims beneficial ownership of these trust shares for Section 16 purposes except to the extent of his pecuniary interest, if any.
What Was Disclosed
The filing reports that Amylyx Pharmaceuticals CFO James M. Frates exercised 40,000 stock options and sold 40,000 shares of common stock over November 9-10, 2026, under a pre-established Rule 10b5-1 plan, leaving him with 233,625 directly held shares and 323,835 remaining vested options.



Please wait processing your request...